What happened to the Mesoblast Limited (ASX:MSB) share price?

After surging to a new 52-week in September, the Mesoblast Limited (ASX:MSB) share price has collapsed dramatically recently. Let's look at the reason for its decline, and investigate whether the company is still a good investment.

| More on:
falling asx share price represented by woman making sad face

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After surging to a 52-week high of $5.70 by late September, shares in ASX biotechnology company Mesoblast Limited (ASX: MSB) have come crashing back down to earth this month. The company has shed close to 45% of its market cap in the last few weeks, after receiving an underwhelming response from the US Federal Drugs Administration (FDA) concerning its flagship treatment, remestemcel-L, marketed under the brand name RYONCIL. As of Friday afternoon, Mesoblast shares were trading at just $3.11.

The funny thing is that this has all happened before. Back in August, the Mesoblast share price plunged almost 40% after nervous investors sparked a sell-off, fearing a negative outcome from a meeting between Mesoblast and the Oncologic Drugs Advisory Committee (ODAC), an independent panel that advises the FDA. In that instance, the committee voted overwhelmingly that the available data supported the efficacy of RYONCIL in paediatric patients. Once the market learned of the positive outcome, the Mesoblast share price rebounded just as swiftly.

This time around, things haven't worked out so well for Mesoblast. So, what is actually happening here?

Despite the advice from ODAC, the FDA stated that it would like Mesoblast to conduct at least one more study to prove the effectiveness of RYONCIL. This comes as a pretty heavy blow to Mesoblast, as the company had already been making preparations to launch RYONCIL in the US. These plans will now all need to be put on hold while Mesoblast conducts the additional study – this means potentially significant delays and possibly significant investment.

No wonder the market reacted with shock and investors decided to dump their shares.

But it's also bad news for patients. RYONCIL is designed to treat various inflammatory diseases including chronic heart failure and graft versus host disease (GvHD). GvHD is a potentially life-threatening complication that can occur in up to 50% of cancer patients who have received a bone marrow transplant. Currently, there is no approved treatment in the US for GvHD in children under 12.

Mesoblast is now applying for an accelerated approval with the FDA, which could mean RYONCIL would be approved, but under the condition that a further study is conducted. And meanwhile, it is conducting a phase 3 trial using RYONCIL as a treatment for sufferers of acute respiratory distress syndrome (ARDS) brought on by coronavirus.

In a press release, Mesoblast CEO Dr Silviu Itescu said that the company is "working tirelessly to bring remestemcel-L to patients with life-threatening inflammatory conditions, including SR-aGVHD [steroid-refractory acute graft versus host disease] and COVID-19 ARDS."

Where to from here?

I have to admit to being quite bullish on Mesoblast, so it's disappointing that they haven't come away from their meeting with the FDA with a better outcome, particularly after ODAC voted so resoundingly in their favour. However, this does show the extreme volatility that can occur in the share prices of companies like Mesoblast, where a great deal of their commercial viability is dependent on a single event.

That being said, I think Mesoblast is still definitely worth keeping on your watch list as a possible future growth stock. Their technology is cutting edge and they still have significant cash on hand after a capital raise back in May. However, in the meantime, perhaps your money would be better invested in more mature and diversified healthcare companies like ResMed CDI (ASX: RMD) or CSL Limited (ASX: CSL).

Rhys Brock has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A worried man holds his head and look at his computer.
Share Fallers

Why 29Metals, Brainchip, Platinum, and Premier Investments shares are falling today

These ASX shares are having a tough time on hump day.

Read more »

Man with his head in his head because of falling share price.
Share Fallers

Why 29Metals, Atlas Arteria, IDP Education, and Mineral Resources shares are falling

These ASX shares are having a tough time on Tuesday. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why ALS, EOS, NRW, and Patriot Battery Metals are dropping today

These ASX shares are starting the week in the red.

Read more »

A man looking at his laptop and thinking.
Technology Shares

Why are these ASX tech shares getting smashed today?

Owners of these two stocks are missing out today.

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Share Fallers

Why AGL, Brickworks, IGO, and New Hope shares are dropping today

These ASX shares are having a poor session. But why?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why Amcor, Arafura, Brainchip, and South32 shares are tumbling today

These ASX shares are having a tough time on hump day. But why?

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Why Aussie Broadband, Liontown, Metals Acquisition, and Seek shares are falling

These ASX shares are having a poor session. But why?

Read more »